FDA Panel Recommends Six of Seven Peptides for Compounding List

An FDA advisory panel voted July 23–24, 2026 to recommend six of seven peptides — including BPC-157, KPV, TB-500, and MOTS-c — for the agency's bulk compounding list. If FDA adopts the recommendation, compounding pharmacies could continue producing these widely used products, none of which carry formal FDA drug approval. The panel's vote is advisory; no final decision timeline has been announced.